PACB logo

PACB
Pacific Biosciences of California Inc

14,402
Mkt Cap
$398.64M
Volume
8.21M
52W High
$2.73
52W Low
$0.8511
PE Ratio
-0.74
PACB Fundamentals
Price
$1.35
Prev Close
$1.32
Open
$1.36
50D MA
$1.70
Beta
2.04
Avg. Volume
5.89M
EPS (Annual)
-$1.82
P/B
76.23
Rev/Employee
$329,907.22
$983.82
Loading...
Loading...
News
all
press releases
Here's Why You Should Add PacBio Stock to Your Portfolio Now
PACB's strong Q4 results, expanding sequencing tech portfolio and rising system adoption highlight growth momentum despite ongoing purchasing cycle challenges.
Zacks·9h ago
News Placeholder
More News
News Placeholder
Pacific Biosciences of California (PACB) Registers a Bigger Fall Than the Market: Important Facts to Note
The latest trading day saw Pacific Biosciences of California (PACB) settling at $1.26, representing a -6.67% change from its previous close.
Zacks·5d ago
News Placeholder
PacBio Wins Basecamp Research Deal for Trillion Gene Atlas Initiative
PACB wins Basecamp deal to power Trillion Gene Atlas using HiFi sequencing, advancing AI-driven drug discovery with high-accuracy genomic data.
Zacks·7d ago
News Placeholder
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Consensus Rating of "Hold" by Brokerages
Pacific Biosciences of California, Inc. (NASDAQ:PACB - Get Free Report) has been given an average rating of "Hold" by the seven analysts that are covering the stock, Marketbeat reports. Two research...
MarketBeat·9d ago
News Placeholder
Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know
In the closing of the recent trading day, Pacific Biosciences of California (PACB) stood at $1.33, denoting a -5% move from the preceding trading day.
Zacks·12d ago
News Placeholder
Pacific Biosciences (PACB) Upgraded to Strong Buy: What Does It Mean for the Stock?
Pacific Biosciences (PACB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·14d ago
News Placeholder
COO Declines Despite Q1 Earnings Beat and Raised FY26 Outlook
Cooper Companies tops Q1 EPS estimates and lifts FY26 outlook as MyDay and MiSight drive growth. Shares slip despite solid margin expansion.
Zacks·26d ago
News Placeholder
Pacific Biosciences of California (NASDAQ:PACB) Receives Underweight Rating from Barclays
Barclays reissued an "underweight" rating and issued a $1.50 price objective on shares of Pacific Biosciences of California in a research report on Friday...
MarketBeat·26d ago
News Placeholder
Christian Henry Sells 12,497 Shares of Pacific Biosciences of California (NASDAQ:PACB) Stock
Pacific Biosciences of California, Inc. (NASDAQ:PACB - Get Free Report) insider Christian Henry sold 12,497 shares of the company's stock in a transaction that occurred on Tuesday, March 3rd. The...
MarketBeat·27d ago
News Placeholder
Clover Health Enters Collaboration to Be Part of CMS Aligned Network
CLOV jumped 8% after partnering with Kno2 to become the first payer live on a CMS Aligned Network, enabling real-time patient access to clinical and claims data.
Zacks·27d ago
<
1
2
...
>

Latest PACB News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.